newdrugapprovals.org
FDA approves first-of-its kind targeted RNA-based therapy Onpattro (patisiran) to treat a rare disease
FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease First treatment for the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adult patients The U.S. …